|
|
Article: Accentia Biopharmaceuticals Announces that Revimmune is Profiled in Hopkins Medicine Magazine.(Reprint)
- Article from:
- Business Wire
- Article date:
- January 29, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that Hopkins Medicine Magazine has published an article in its Winter 2008 edition profiling Revimmune[TM] as a potential cure for a host of autoimmune diseases.
The article, titled, "High Time for HiCy" chronicles the history of the development of Revimmune (high-dose cyclophosphamide or HiCy). Elaine Freeman reports on studies conducted by Johns Hopkins University researchers using Revimmune which show remarkable promise, as well as durable remissions and potential cures for autoimmune diseases, such as multiple sclerosis, myasthenia gravis, scleroderma, severe aplastic anemia, and ...